Literature DB >> 21270530

It never rains but it pours: potential role of butyrophilins in inhibiting anti-tumor immune responses.

Juan R Cubillos-Ruiz, Jose R Conejo-Garcia.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21270530      PMCID： PMC3115012          DOI： 10.4161/cc.10.3.14565

Source DB:  PubMed          Journal:  Cell Cycle        ISSN： 1551-4005            Impact factor:   4.534


× No keyword cloud information.
  10 in total

1.  Frontline: Characterization of BT3 molecules belonging to the B7 family expressed on immune cells.

Authors:  Elsa Compte; Pierre Pontarotti; Yves Collette; Marc Lopez; Daniel Olive
Journal:  Eur J Immunol       Date:  2004-08       Impact factor: 5.532

2.  BTNL2, a butyrophilin-like molecule that functions to inhibit T cell activation.

Authors:  Thang Nguyen; Xikui K Liu; Yongliang Zhang; Chen Dong
Journal:  J Immunol       Date:  2006-06-15       Impact factor: 5.422

3.  Stimulation of human butyrophilin 3 molecules results in negative regulation of cellular immunity.

Authors:  Hiromichi Yamashiro; Shinji Yoshizaki; Toshimasa Tadaki; Kohji Egawa; Naohiro Seo
Journal:  J Leukoc Biol       Date:  2010-07-07       Impact factor: 4.962

4.  Sarcoidosis is associated with a truncating splice site mutation in BTNL2.

Authors:  Ruta Valentonyte; Jochen Hampe; Klaus Huse; Philip Rosenstiel; Mario Albrecht; Annette Stenzel; Marion Nagy; Karoline I Gaede; Andre Franke; Robert Haesler; Andreas Koch; Thomas Lengauer; Dirk Seegert; Norbert Reiling; Stefan Ehlers; Eberhard Schwinger; Matthias Platzer; Michael Krawczak; Joachim Müller-Quernheim; Manfred Schürmann; Stefan Schreiber
Journal:  Nat Genet       Date:  2005-02-27       Impact factor: 38.330

5.  A butyrophilin family member critically inhibits T cell activation.

Authors:  Tomohide Yamazaki; Iñigo Goya; Daniel Graf; Suzanne Craig; Natalia Martin-Orozco; Chen Dong
Journal:  J Immunol       Date:  2010-10-13       Impact factor: 5.422

6.  BTNL2, a butyrophilin/B7-like molecule, is a negative costimulatory molecule modulated in intestinal inflammation.

Authors:  Heather A Arnett; Sabine S Escobar; Eva Gonzalez-Suarez; Alison L Budelsky; Lori A Steffen; Norman Boiani; Ming Zhang; Gerald Siu; Avery W Brewer; Joanne L Viney
Journal:  J Immunol       Date:  2007-02-01       Impact factor: 5.422

7.  Risk of ovarian cancer and inherited variants in relapse-associated genes.

Authors:  Abraham Peedicayil; Robert A Vierkant; Lynn C Hartmann; Brooke L Fridley; Zachary S Fredericksen; Kristin L White; Elaine A Elliott; Catherine M Phelan; Ya-Yu Tsai; Andrew Berchuck; Edwin S Iversen; Fergus J Couch; Prema Peethamabaran; Melissa C Larson; Kimberly R Kalli; Matthew L Kosel; Vijayalakshmi Shridhar; David N Rider; Mark Liebow; Julie M Cunningham; Joellen M Schildkraut; Thomas A Sellers; Ellen L Goode
Journal:  PLoS One       Date:  2010-01-27       Impact factor: 3.240

8.  CD277 is a negative co-stimulatory molecule universally expressed by ovarian cancer microenvironmental cells.

Authors:  Juan R Cubillos-Ruiz; Diana Martinez; Uciane K Scarlett; Melanie R Rutkowski; Yolanda C Nesbeth; Ana L Camposeco-Jacobs; Jose R Conejo-Garcia
Journal:  Oncotarget       Date:  2010-09

Review 9.  Inhibitory B7-family molecules in the tumour microenvironment.

Authors:  Weiping Zou; Lieping Chen
Journal:  Nat Rev Immunol       Date:  2008-06       Impact factor: 53.106

10.  BTN1A1, the mammary gland butyrophilin, and BTN2A2 are both inhibitors of T cell activation.

Authors:  Isobel A Smith; Brittany R Knezevic; Johannes U Ammann; David A Rhodes; Danielle Aw; Donald B Palmer; Ian H Mather; John Trowsdale
Journal:  J Immunol       Date:  2010-03-05       Impact factor: 5.422
  10 in total
  5 in total

Review 1.  The butyrophilin (BTN) gene family: from milk fat to the regulation of the immune response.

Authors:  Hassnae Afrache; Philippe Gouret; Shanaiz Ainouche; Pierre Pontarotti; Daniel Olive
Journal:  Immunogenetics       Date:  2012-09-23       Impact factor: 2.846

Review 2.  Immune modulation by butyrophilins.

Authors:  Heather A Arnett; Joanne L Viney
Journal:  Nat Rev Immunol       Date:  2014-08       Impact factor: 53.106

3.  Modulating the tumor immune microenvironment as an ovarian cancer treatment strategy.

Authors:  Uciane K Scarlett; Jose R Conejo-Garcia
Journal:  Expert Rev Obstet Gynecol       Date:  2012-09-01

4.  A common 56-kilobase deletion in a primate-specific segmental duplication creates a novel butyrophilin-like protein.

Authors:  Johanna Aigner; Sergi Villatoro; Raquel Rabionet; Jaume Roquer; Jordi Jiménez-Conde; Eulàlia Martí; Xavier Estivill
Journal:  BMC Genet       Date:  2013-07-06       Impact factor: 2.797

5.  BTN3A2 expression in epithelial ovarian cancer is associated with higher tumor infiltrating T cells and a better prognosis.

Authors:  Cécile Le Page; Alexandre Marineau; Patrick K Bonza; Kurosh Rahimi; Louis Cyr; Ingrid Labouba; Jason Madore; Nathalie Delvoye; Anne-Marie Mes-Masson; Diane M Provencher; Jean-François Cailhier
Journal:  PLoS One       Date:  2012-06-07       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.